retatrutide trial results news Lilly's triple agonist achieves 16.8% weight loss in phase 3 Eli Lilly retatrutide Phase 3

However, it provides an option for individuals trying to improve their metabolic health without needing big treatments

Disclosure This article has been written independently and reflects solely the opinion of the authors without any potential conflict of interest

Every patient reacts differently to different Vitamin B12 types

ONE SIZE FITS NONE Personalized protocols, tuned to your body

Women with severe vasomotor symptoms should be treated with hormone therapy at the lowest dose possible per guidelines, and tirzepatide should remain top-of-the-list for weight loss in persons with obesity or overweight with comorbid illness, Uzmann says